AC Immune SA is a clinical-stage biopharmaceutical company leading in precision medicine for neurodegenerative diseases driven by misfolded proteins, including Alzheimer's, Parkinson's, and NeuroOrphan diseases.
We are advancing one of the industry's broadest and most diverse clinical-stage pipelines of first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling our comprehensive precision medicine approach.
Our productivity stems from our staff's knowledge and experience coupled with our two clinically validated technology platforms, SupraAntigen® and Morphomer®, which we use to design and develop novel, proprietary diagnostics and medicines for diagnosis, treatment and prevention of neurodegenerative diseases.
Multiple strategic alliances with leading industry partners like Takeda, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company) and Eli Lilly and Company, have already generated more than CHF450 million in funding and prove the value of our discovery and development capabilities.
AC Immune is pursuing a clear three pillar execution strategy:
- Accelerate development of Alzheimer's disease therapeutics
- Expand into Parkinson's and NeuroOrphan diseases
- Advance precision medicine-enabling diagnostics
Investment Highlights
- Short- to mid-term value:
Maturing wholly-owned pipeline of clinical and preclinical assets
- De-risked long-term value:
3 best-in-class active immunotherapies in mid-stage clinical development
- New breakthroughs:
Proprietary discovery platforms have repeatedly proven to be value-creating
- Partnering:
Strategic, risk-mitigating, and timely monetization with over CHF 4 billion in potential milestones
- Cash reserves on balance sheet
Funding into 2027
Minimum 15 minutes delayed. Source: LSEG
